» Articles » PMID: 15193681

Increased Left Ventricular Mass is a Risk Factor for the Development of a Depressed Left Ventricular Ejection Fraction Within Five Years: the Cardiovascular Health Study

Overview
Date 2004 Jun 15
PMID 15193681
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Our aim in this study was to determine whether increased left ventricular mass (LVM) is a risk factor for the development of a reduced left ventricular ejection fraction (LVEF).

Background: Prior studies have shown that increased LVM is a risk factor for heart failure but not whether it is a risk factor for a low LVEF.

Methods: As part of the Cardiovascular Health Study, a prospective population-based longitudinal study, we performed echocardiograms upon participant enrollment and again at follow-up of 4.9 +/- 0.14 years. In the present analysis, we identified 3,042 participants who had at baseline a normal LVEF and an assessment of LVM (either by electrocardiogram or echocardiogram), and at follow-up a measurable LVEF. The frequency of the development of a qualitatively depressed LVEF on two-dimensional echocardiography, corresponding approximately to an LVEF <55%, was analyzed by quartiles of baseline LVM. Multivariable regression determined whether LVM was independently associated with the development of depressed LVEF.

Results: Baseline quartile of echocardiographic LVM indexed to body surface area was associated with development of a depressed LVEF (4.8% in quartile 1, 4.4% in quartile 2, 7.5% in quartile 3, and 14.1% in quartile 4 [p < 0.001]). A similar relationship was seen in the subgroup of participants without myocardial infarction (p < 0.001). In multivariable regression that adjusted for confounders, both baseline echocardiographic (p < 0.001) and electrocardiographic (p < 0.001) LVM remained associated with development of depressed LVEF.

Conclusions: Increased LVM as assessed by electrocardiography or echocardiography is an independent risk factor for the development of depressed LVEF.

Citing Articles

Age-dependent hypertrophy and fibrosis dynamics in hypertrophic cardiomyopathy: Insights from longitudinal CMR studies.

Haberkorn S, Rana M, Koch V, Martin S, Vogl T, Leistner D Int J Cardiol Heart Vasc. 2024; 55:101546.

PMID: 39555491 PMC: 11564995. DOI: 10.1016/j.ijcha.2024.101546.


Genetic basis of right and left ventricular heart shape.

Burns R, Young W, Aung N, Lopes L, Elliott P, Syrris P Nat Commun. 2024; 15(1):9437.

PMID: 39543113 PMC: 11564811. DOI: 10.1038/s41467-024-53594-7.


Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated.

Fazio S, Mercurio V, Tibullo L, Fazio V, Affuso F Front Cardiovasc Med. 2024; 11:1380506.

PMID: 38545338 PMC: 10965550. DOI: 10.3389/fcvm.2024.1380506.


Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition.

Wu Q, Liu W, Ma X, Chang J, Zhao X, Liu Y Acta Pharmacol Sin. 2023; 45(4):738-750.

PMID: 38097716 PMC: 10943222. DOI: 10.1038/s41401-023-01191-7.


Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease.

Pogoda C, Brand S, Duning T, Schmidt-Pogoda A, Sindermann J, Lenders M Front Cardiovasc Med. 2023; 10:1223635.

PMID: 38028489 PMC: 10656767. DOI: 10.3389/fcvm.2023.1223635.